Acer Therapeutics’ bid to repurpose celiprolol — a beta-blocker on the market for hypertension — as a treatment for a rare, inherited connective tissue disorder has hit a severe setback. The Newton, Massachusetts-based company on Tuesday said the FDA rejected the drug and has asked for another clinical trial.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,